Created by CREW

CREW: Food And Drug Administration: Regarding Communications Between the FDA and Martin Shkreli

On July 28, 2011, as part of a larger effort to ascertain the extent to which Wall Street investors are attempting to influence agency policy and regulation, CREW sent a Freedom of Information Act (FOIA) request to the Food and Drug Administration. CREW’s request seeks records of all communications between FDA and Martin Shkreli, CEO of the hedge fund MSMB Capital Management. Mr. Shkreli already has sought to influence the FDA’s drug approval process based on companies in which he held short positions.